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Abstract The anti-inflammatory/immunoparalytic phase
of the systemic inflammatory response syndrome (SIRS)
following major insult (surgery, thermal/traumatic in-
jury) is of major clinical importance in the neonate,
during which the risk of infection is particularly great.
Here, the mechanisms by which TNF-a production is
suppressed in response to infection are largely unknown.
We questioned whether TNF-a itself could be a critical
mediator of this suppression. Monocytes, isolated from
cord blood (n=3), were treated with LPS (100 ng/ml),
TNF-a (10 ng/ml, +/ anti-TNF-a antibody) for 18
and 36 h. Cells were then restimulated with LPS (Gram
ve) or Pam-3-Cys (Gram +ve) for 24 h. This was also
done in the presence of selective inhibitors of MAP
kinases p38, MEK and JNK. TNF-a, IL-6, IL-10 and
IL-8 were quantified by ELISA CD86 and HLA-DR
expression were determined flow cytometrically. Cells
stimulated with LPS for 24 h produced TNF-a (282 pg/
ml), IL-10 (1,236 pg/ml), IL-6 (2,694 pg/ml) and IL-8
(2,144 pg/ml). In cells pre-exposed to TNF-a for 36 h,
there was a significant suppression in TNF-a and IL-6
levels (9 and 221 pg/ml, respectively) (P<0.05) with
minimal impact on IL-10 (1,206 pg/ml) and IL-8 levels
(1,886 pg/ml). A similar effect was seen with Pam-3-Cys
with a tenfold decrease in levels of TNF-a and IL-6
(86 fi 8.5 pg/ml and 458 fi 46 pg/ml, respectively) with
no effect on IL-10 and IL-8 levels. Anti-TNF-a antibody
negated this effect. Inhibition of p38 kinase reversed the
TNF-a effect. Inhibition of the JNK and MEK kinases
had no effect. A reduction in the expression of CD86
and HLA-DR was observed. This ex-vivo model of
non-septic SIRS demonstrates that TNF-a, released
during a major insult, can suppress subsequent mono-
cyte responses to bacterial agents through p38 MAP
kinase, making it a potential therapeutic target.
Keywords Neonatal sepsis Æ Monocyte
tolerance Æ TNF-a
Introduction
The systemic inflammatory response syndrome (SIRS)
occurs where there is inappropriate activation of the
immune system [1]. While the initiating events leading to
SIRS may be varied, e.g. sepsis, thermal injury, trauma
or post major surgery, the subsequent immune patho-
physiology following these events is identical [2]. The
characteristics of this syndrome are initial massive re-
lease of pro-inflammatory cytokines, principally TNF-a
and IL1-b followed by anergy of the immune system
termed ‘‘immunoparalysis’’ and production of the anti-
inflammatory cytokines IL-10 and TGF-b termed the
‘‘compensatory anti-inflammatory response’’ (CARS) [2,
3]. Recent work in both adult [4, 5] and paediatric
populations [6, 7] has identified monocyte and macro-
phage deactivation, which occurs as part of the immu-
noparalytic phenomenon, as a major predictor for the
development of nosocomial infection with restoration of
cellular function associated with improvement in the
clinical condition of patients [8, 9]. Improved under-
standing of the factors causing monocyte/macrophage
deactivation has been aided by the realisation that the ex
vivo tolerant monocyte possesses the same functional
phenotype as its in vivo immunoparalytic counterpart
[10–12]. Innate tolerance was originally described with
respect to endotoxin and is classically defined as failure
of a secondary TNF-a response from a macrophage/
monocyte following initial low dose stimulation [13, 14].
There has been no published literature regarding
neonatal innate tolerance despite its importance in the
development of nosocomial infections, an important
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predictor of mortality in the critically ill neonate [15].
The aim of this study was to assess the ability of neo-
natal monocytes to undergo tolerance induction. In or-
der to mimic the clinical situation of sepsis,
lipopolysaccharide [LPS] and Pam-3- Cys were used.
LPS is found in the cell wall of gram-negative bacteria
and signals through toll-like receptor (TLR) 4 while
Pam-3-Cys is an agonist of TLR2, the surface receptor
for gram-positive bacteria [16]. Recreation of the non-
septic situation was performed by exposing neonatal
monocytes to TNF-a, representing the initial non-septic
insult e.g. surgery and then restimulating these mono-
cytes with LPS or Pam-3-Cys representing the bacterial
challenge which the critically ill post-operative neonate
commonly encounters in the intensive care environment.
Material and methods
Materials
IMDM and HBSS were purchased from BioWhitaker
(Wokingham, UK). Human recombinant TNF-a and
anti-human TNF-a antibody were purchased from R
and D systems (Oxon, UK). LPS (Escherichia coli
serotype 055:B5) was obtained from Sigma-Aldrich
(Dublin, Ireland). Pam-3- Cys (N-Palmitoyl-S-(17)-(18)-
cysteinyl-(18)-seryl-(18)-lysl-(18)-lysl-(18)-lysl-(18)-ly-
sine·3 HCL) was obtained from EMC microcollections
(Tuebingen, Germany). Anti-human CD14(PE) CD45
(FITC) mouse anti-human CD45(clone MOPC-
21)IgG1, mouse anti-human (clone 2D1M/P)IgG2a
human anti-TNF(APC) and mouse anti-human (clone
Mab11)IgG1 were purchased from BD Biosciences
(Oxford, UK). SB203580, PD98059, SP600125,
SB202474 and JNK inhibitor negative control, N-me-
thyl-1,9-pyrazoloanthrone were purchased from Cal-
biochem (Nottingham, UK).
Every effort was made to ensure minimal contami-
nation with LPS in our system. All steps in monocyte
purification protocols and culturing were conducted
using certified non-pyrogenic plastics (Corning/Costar,
Bucks, UK) and media certified to have an endotoxin
level of 0.005 endotoxin U/ml (BioWhittaker). All
solutions were made up with endotoxin-free water
(Nanopure, Barnstead, UK)
Monocyte isolation
Cord blood was obtained with full consent following
full-term normal deliveries. This was then diluted 1/1
with HBSS. PBMCs were separated by density centri-
fugation through Ficoll–Hypaque (Lymphoprep, Ny-
comed, Oslo, Sweden), washed twice in cold HBSS and
resuspended in IMDM (1 ml) and PBMC count deter-
mined by ethidium bromide and acridine orange stain-
ing. Monocytes were isolated from PBMCs by negative
selection according to the manufacturer’s protocol
(Miltenyi Biotec, Surrey, UK). Monocyte purity, deter-
mined flow cytometrically using two-colour flow cyto-
metric analysis (CD14/CD45), was >80%.
Analysis of cytokines
Cytokine concentrations in the cellular supernatants
were determined by ELISA using TNF-a-matched Ab
pairs (R&D Systems) and OptEIA human IL-10, IL6
and IL-8 sets (BD Pharmingen, Oxford, UK). Assays
were performed according to the instructions provided.
Colour development was assessed using a VERSA-max
microplate reader (Biosciences, Dublin, Ireland). Intra-
cellular cytokine estimation was performed as described
previously [19]. Cells were stained with surface markers
CD14FITC, CD45PerCp, HLA-DRPE, CD86FITC and
CD80 Cy-chrome (BD, Pharmingen) at room tempera-
ture for 10 min. Cells were washed with ice-cold PBS
and following this were fixed with Cytofix (Pharmingen,
San Diego, USA) for 20 min at 4C. Cells were then
permeabilised with ice-cold permwash (Pharmingen, San
Diego, USA), washed and resuspended in 100 ll of
PBA. The intracellular antibody TNF-aAPC was then
added for 30 min at room temperature. The cells were
then washed in ice-cold permwash, resuspended in
200 ll of PBA and assessed by flow cytometry.
Statistical analysis
The Mann–Whitney non-parametric test was performed
using the software SPSS for Windows.
Results
We first examined the primary cytokine output from the
proposed tolerising agents. Figure 1a demonstrates the
cytokine output from neonatal monocytes stimulated
with LPS. There is significantly less (P<0.005) TNF-a
and IL-10 production from neonatal monocytes in
comparison to their adult counterparts. Interestingly,
there are comparable levels of IL-1b, IL-6 and IL-8
production. Pam-3-Cys is not as potent a stimulus as
LPS and this is reflected in Fig. 1b where there is a
global reduction in measured cytokine levels. Neonatal
monocytes produce significantly less (P<0.01) TNF-a
and IL-10 in relation to their adult counterparts in
common with Fig. 1a. Similarly IL1-b, IL-6 and IL-8
levels are comparable with adult monocytes. TNF-a
stimulation of neonatal and adult monocytes is shown in
Fig. 1c. There is a significant reduction (P<0.05) in the
amount of IL-10 produced from neonatal monocytes
with no significant attenuation noted in relation to IL-6
and IL-8. There were no measurable levels of IL-1b
produced from either neonatal or adult monocytes.
TNF-a could not be measured by ELISA due to
the presence of exogenous TNF-a in the cellular
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supernatant. Neonatal monocytes are capable of
undergoing tolerance to LPS and Pam-3-Cys with the
same time kinetic as adult monocytes (Fig. 2a). Innate
tolerance is defined as a lack of TNF-a production on
secondary stimulation. Neonatal monocytes treated with
either LPS or Pam-3-Cys and then restimulated 18 hr
later with higher doses of the same stimulus for a further
24 h failed to produce TNF-a in comparison to those
cells which did not receive the initial low dose stimula-
tion. We next looked at TNF-a as an inducer of toler-
ance. The current dogma is that TNF-a is not capable of
tolerance induction [20, 21]. This is shown in Fig. 3a
where at 18 h there is still a substantial secondary TNF-
a response following secondary LPS or Pam-3-Cys
stimulation. Interestingly, when the TNF-a pre-treat-
ment time kinetic is extended to 36 h, TNF-a causes
tolerance as judged by lack of TNF-a production on
secondary stimulation with LPS and Pam-3-Cys. Sub-
stantial amounts of IL-10 and IL-8 are produced from
these TNF-a tolerant cells with a significant reduction in
IL-6 secretion (P<0.05), in keeping with the idea that
tolerant cells exhibit a reorientation of their functional
phenotype as opposed to a global reduction in the
cytokine producing capacity of the monocyte.
Further evidence that TNF-a is acting as a tolerising
agent is provided by analysis of the surface antigens
CD86 and HLA-DR. Downregulation of both HLA-
DR and CD86 is present in the TNF-a tolerant cell in
common with published results on LPS tolerance
induction [22] (Fig. 4a, b).
Neutralisation of TNF-a was performed using anti-
TNF-a antibody to ensure that the results obtained were
due exclusively to TNF-a. In the presence of anti-TNF-
a, tolerance does not occur as evidenced by a substantial
TNF-a response following secondary LPS stimulation
(Fig. 5a). To elucidate the mechanisms of TNF-a toler-
ance induction, specific inhibitors of the MAP kinase
pathway were employed. The MAP kinase pathway is
one of the chief pathways activated by TNF-a [23, 24].
The MAP kinase proteins ERK, JNK and p38 are
phosphorylated leading to activation of downstream
mediators resulting in gene transcription and ultimately
cytokine production [25].
The inhibitors SP600125, PD98059 and SB 203580
prevent phosphorylation of JNK, ERK and p38,
respectively [26–28]. While inhibition of ERK and JNK
does not prevent TNF-a from inducing tolerance, inac-
tivation of p38 by SB 203580 does, as evidenced by a
substantial TNF-a response upon secondary LPS stim-
ulation (Fig. 5b).
Discussion
There has been much discussion in the literature over the
last decade regarding the role of the monocyte in the
neonatal immune response. The rapidity of clinical
deterioration in septic neonates suggests an inefficiency
Fig. 1 A quantity of 0.5·106/ml
of neonatal and adult
monocytes were cultured in
IMDM/10% autologous serum
and stimulated with a LPS
(1 lg/ml), b Pam-3 Cys (1 lg/
ml) or c human recombinant
TNF-a (1 lg/ml) for a period of
24 h. Following this time point
the cellular supernatant was
collected and stored at 70C
until analysed by ELISA
(n=6). Data representative of
mean ± SD
Fig. 2 A quantity of 0.5·106/ml neonatal and adult monocytes
were cultured for 18 h with LPS (100 ng/ml) or Pam-3-Cys
(100 ng/ml) for 18 h. The cells were then washed twice and
restimulated with LPS (1 lg/ml) or Pam-3-Cys (1 lg/ml) for a
further 24 h. The cellular supernatant was collected and stored at
70C until analysed. TNF-a was measured by ELISA (n=5).
Data representative of mean ± SD
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of the innate immune system to mount an effective re-
sponse allowing rapid progression to multiple organ
dysfunction [29].The data presented here agrees with the
published literature demonstrating that neonatal
monocytes produce equivalent levels of IL-6, IL-8 and
IL1-b, with TNF-a the only element of the pro-inflam-
matory response to exhibit reduced levels following LPS
and Pam-3-Cys stimulation [30–33]. The results also
show that IL-10 production is significantly reduced in
relation to adult monocytes following stimulation with
LPS, Pam-3-Cys and TNF-a. Signal transduction of
LPS and Pam-3-Cys occurs via the surface receptors
TLR4 and TLR 2, respectively [17, 34]. Activation of
these surface receptors ultimately leads to gene tran-
scription of both pro- and anti-inflammatory cytokines
[35]. The finding that neonatal monocytes produce
comparable levels of the pro-inflammatory cytokines
IL-6, IL-8 and IL-1b suggests, in agreement with pub-
lished studies [30], that similar amounts of TLR recep-
tors are present on the cell surface of neonatal
monocytes and that the discrepancies seen in relation to
TNF-a and IL-10 production as illustrated here are due
to distinct inherent deficiencies present in the neonatal
monocyte in relation to the pathways involved specifi-
cally in TNF-a and IL-10 production. This data coupled
with published work on the other main anti-inflamma-
tory cytokine TGF-b illustrate clearly that both com-
ponents of the neonatal anti-inflammatory response are
deficient [36]. One could argue that a factor leading to
rapid deterioration of the septic neonate is inefficient
counterbalancing of the anti-inflammatory component
of the inflammatory response resulting in a predomi-
nance of the pro-inflammatory element of the neonatal
innate immune response occurring as a result of inherent
deficiencies within the neonatal cell as opposed to the
virulence of the infecting organism as is the case in
adults.
Inappropriate monocyte activation is central to the
initiation and progression of SIRS. Activation of
monocytes following any major insult results in massive
and inappropriate release of the pro-inflammatory
cytokines TNF-a, IL1-b, IL-6 and IL-8 [37]. In large
quantities these cytokines cause a reduction in vascular
tone and myocardial contractility resulting in hypoten-
sion [38]. They also stimulate release of tissue factor, a
potent activator of coagulation, from endothelial cells
and cause a reduction in expression of thrombomodulin,
an inhibitor of coagulation, resulting in intravascular
thrombosis [39].
Fig. 3 A quantity of 0.5·106/ml
neonatal monocytes were
stimulated with TNF-a (10 ng/
ml) for 18 and 36 h. These cells
were then washed extensively
and restimulated with LPS
(1 lg/ml) or Pam-3-Cys (1 lg/
ml) for a further 24 h.
Following this time period
cellular supernatant was
collected and stored at 70C
until further analysis. TNF-a, I
L-10,IL-6 and IL-8 were
measured by ELISA (n=3).
Data representative of mean ±
SD
Fig. 4 A quantity of 0.5·106/ml neonatal monocytes were stimu-
lated with TNF-a (10 ng/ml) for 36 h. Cells were then washed twice
and restimulated with LPS (1 lg/ml) for a further 24 h. Cells were
harvested and stained for 30 min with a CD86 and b HLA-DR.
Following this time period, cells were assessed for surface
expression of both molecules by flow cytometry (n=3). Data
representative of mean ± SD
27
The net effect of these events is hypoxia of tissues and
organs, causing ischemic injury, further activating the
immune response and a viscous cycle ensues [40, 41].
From an immunological standpoint, the mechanisms
governing the inflammatory response are disrupted due
to the inappropriate pro-inflammatory response and a
prolonged period of immunoparalysis and predomi-
nance of anti-inflammatory cytokine production ensues.
This period in SIRS has also been referred to as
‘‘CARS’’ [2, 36].
Monocytes from patients in CARS are identified as
failing to mount a secondary TNF-a response fol-
lowing stimulation and also exhibit a downregulation
of the surface receptors CD86 and HLA-DR [42–44].
These receptors are important in presentation of the
foreign antigen to the T cells of the adaptative im-
mune system and so activation of the adaptative im-
mune system is hindered while this downregulation is
present [45]. Not surprisingly, patients are more sus-
ceptible to invading organisms during this period
causing further monocyte activation and a viscous
cycle is created leading to multiple organ dysfunction
syndrome (MODS) with its associated high mortality
rates.
The monocyte phenotype from patients in CARS is
identical to the ex-vivo tolerant monocyte [10–12]
allowing ex vivo investigation into the many mediators
involved in the creation of the immunoparalysis wit-
nessed in the CARS phase of SIRS.
The results from our study illustrate that neonatal
monocytes are capable of tolerance induction by LPS
and Pam-3-Cys in a manner identical to their adult
counterparts. This implies that similar kinetics of im-
munoparalysis exist in the septic Gram-positive and
Gram-negative neonate making therapeutic interven-
tions, e.g. the use of interferon gamma to reverse im-
munoparalysis, already successfully tried in the adult
population, a distinct possibility in the neonatal popu-
lation [8, 9].
The immune pathophysiology which occurs in the
non-septic SIRS situation is identical to that in the septic
SIRS situation. While it is agreed that endotoxin is the
main cause of immunoparalysis in septic SIRS, the
causal agents in the non-septic situation have been
harder to define. Reductionist ex vivo investigation into
the mechanisms of tolerance has identified possible roles
for IL1-b, prostaglandins, corticosteroids and IL-10 [21,
46–48].
Interestingly, despite early in vivo adult work
demonstrating evidence of TNF-a tolerance induction
using end points of survival and weight loss [49–51],
more recent ex vivo studies have failed to demonstrate
any role for this cytokine in tolerance induction [20,
52, 53].
The data presented here shows that in the neonatal
monocyte population TNF-a is capable of inducing
tolerance by extension of the tolerising time kinetic. The
36 h kinetic was chosen in an attempt to mirror the
Fig. 5 a A quantity of 0.5·106/ml neonatal monocytes were
stimulated for 36 h with TNF-a (10 ng/ml) in the presence or
absence of anti-TNF-a neutralising antibody. Following this time
period, cells were washed and restimulated with LPS (1 lg/ml) for
a further 4 h. Cells were harvested and stained with TNF-a for
30 min. Estimation of intracellular levels of TNF-a was performed
by flow cytometry (n=3). Data representative of mean ± SD. b
Monocytes were stimulated for 36 h with TNF-a (10 ng/ml) in the
presence or absence of the MAP kinase inhibitors SB203580
(10 lM/ml), PD 98059 (10 lM/ml) and SP600125 (10 lM/ml).
Following this time period, the cells were washed extensively and
restimulated with LPS (1 lg/ml) for a further 24 h. The cellular
supernatant was harvested and stored at 70C until cytokine
estimation was performed using ELISA (n=3). Data representative
of mean ± SD
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longer time point present in the in-vivo work. This
finding is strengthened by our results which also show a
downregulation of CD86 and HLA-DR in keeping with
the tolerant phenotype described in the literature. Tol-
erance is achieved by TNF-a through activation of the
p38 pathway. Interestingly, other investigators have also
shown this result in relation to LPS tolerance induction
in adult cells [54]. This novel finding provides evidence
for the first time that TNF-a, the archetypal pro-
inflammatory cytokine, displays anti-inflammatory
properties by virtue of its involvement in the creation of
immunoparalysis in the non-septic SIRS situation. The
identification of p38 as the critical molecule involved
helps to provide a framework for the development of a
potential therapeutic target in the management of non-
septic SIRS patients in the future.
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